Lexeo Therapeutics Receives Rare Pediatric Disease & Orphan Drug Designations for LX2006
Industry News
News|Jun 30 2021
LEXEO Therapeutics Announces License Agreement and Consolidation of Pre-clinical Data Package to Support Cardiac Friedreich’s Ataxia Gene Therapy Program (LX2006)
Industry News
Blog|Jun 28 2021
Meet the Community – David (Dave) Arnold
Community
Blog|Jun 21 2021
Meet the Community – Leila Filgueiras
Community
Blog|Jun 14 2021
Meet The Community: Nikolaos Kotsomouras
Community
Blog|Jun 7 2021
Meet The Community: Scott Armit
Community
Blog|Jun 1 2021
Meet The Community: Silvana Camaj
Community
Blog|May 24 2021
Meet The Community: Silvany Guimarães Coelho Cotting
Community
News|May 21 2021
Larimar Therapeutics Announces $95 Million Private Placement Financing
Industry News
News|May 20 2021
Larimar Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreich’s Ataxia